AUTHORS
Tim Richardson, MD, Philipp Gödel, MD2, Udo Holtick, MD, PhD3, Christof Scheid4, Elisa Carpinteiro5, Michael Hallek Jr, MD6
AFFILIATIONS
1 University of Cologne, Köln, Germany
2 University of Cologne, Köln, Germany
3 University of Cologne, Köln, Germany
4 University of Cologne, Köln, Germany
5 University of Cologne, Köln, Germany
6 University of Cologne, Köln, Germany
ABSTRACT
Background: Outpatient delivery of chimeric antigen receptor T-cell (CAR-T) therapy remains uncommon in Europe. We previously published a structured fully outpatient pathway for ciltacabtagene autoleucel (cilta-cel) with relapsed/refractory multiple myeloma (RRMM). We now report an expanded fully outpatient cohort together with a novel semi-outpatient pathway combining ambulatory treatment initiation with planned inpatient admission for cytokine release syndrome (CRS) management, representing a significant extension of our prior experience.
Methods: At our tertiary center, cilta-cel-eligible RRMM patients meeting predefined clinical and logistical criteria were treated via one of two structured pathways. Fully outpatient patients received lymphodepletion, infusion, and structured outpatient surveillance (in-person visits 3 times weekly, daily telephone contact, home vital-sign and ICE-score monitoring, 24/7 physician access), with hospitalization only if predefined criteria were met. Semi-outpatient patients received outpatient lymphodepletion and cilta-cel infusion followed by planned inpatient admission around day +4 for structured CRS management. Eligibility for both pathways required ECOG performance status 0-1, adequate organ function, low tumor burden or response to bridging therapy, travel time under 60 minutes to the treatment center, and a dedicated caregiver at home; all patients provided informed consent. CRS and ICANS were graded per ASTCT criteria.
Results: Both pathways were embedded in an institution with prior experience treating approximately 200 in-label cilta-cel patients under standard inpatient care. The fully outpatient cohort now comprises 14 patients (median age 61 years, range 47-73, median 2 prior lines, range 1-9). CRS occurred in 11/14 (78.6%; grade 1, n=10; grade 2, n=1); no ICANS occurred. Four patients required short, unplanned hospitalization (median 3 days, range 1-5) for fever or CRS; Best response was complete response (CR) in 13/14 (92.9%), with follow-up of 3-24 months and no non-relapse mortality.
In the new semi-outpatient cohort (n=20), all patients completed lymphodepletion and cilta-cel infusion in the outpatient setting without upfront hospitalization, then were electively admitted around day +4 or +5 for CRS management; hospitalization lasted 4-9 days depending on time to fever resolution (median 5 days). CRS occurred in all 20 patients (grade 1, n=18; grade 2, n=2); ICANS grade 1 occurred in 1 patient. Tocilizumab was used in 14 patients. One patient developed fever due to a documented infection before the planned admission, managed accordingly; the outpatient phase was otherwise uneventful. At a median follow-up of 6 months, best response was CR in 19/20 (95%), with progressive disease in 1 patient at 3 months.
Across both pathways (n=34), routine inpatient stays of 14-20 days were avoided entirely or substantially shortened, with no ICU admissions and no early mortality in either cohort. Based on a standard inpatient stay of 14-20 days at our center, the fully outpatient pathway reduced inpatient bed-days by an estimated 95% (12 vs approximately 238 bed-days for 14 patients), and the semi-outpatient pathway by an estimated 71% (approximately 100 vs 340 bed-days for 20 patients).
Conclusion: Both fully outpatient and semi-outpatient delivery of cilta-cel are feasible and safe in selected RRMM patients within a structured monitoring framework. To our knowledge, this is the first European report combining fully outpatient and semi-outpatient delivery models for cilta-cel. This analysis extends our initial EHA 2026 report with 22 additional patients and a novel hybrid pathway. Semi-outpatient delivery, combining ambulatory treatment initiation with a brief, planned admission timed to anticipated CRS onset, may offer a pragmatic bridge for centers not yet ready for fully ambulatory care, while preserving most benefits of reduced inpatient utilization. These data support broader, risk-adapted adoption of structured outpatient care models for cilta-cel.
DISCLOSURES
Tim Richardson, MD: Sanofi - Other (including travel support); Takeda - Consultancy (Includes expert testimony); Oncopeptides - Consultancy (Includes expert testimony); Johnson&Johnson - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Kite - Consultancy (Includes expert testimony)